StreetInsider.com News Articles

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: Solas Capital Management, LLC

Fri, 14 Aug 2026 11:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26926969.html

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: Solas Capital Management, LLC

Fri, 14 Aug 2026 11:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26926969.html

Sanuwave Health, Inc. (SNWV) Misses Q2 EPS by 5c

Fri, 07 Aug 2026 05:53:28 -0400

Sanuwave Health, Inc. (NASDAQ: SNWV) reported Q2 EPS of ($0.08), $0.05 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $9.74 million versus the consensus estimate of $11.5 million.

For earnings history and earnings-related data on Sanuwave Health, Inc. (SNWV) click here.

Form 8-K SANUWAVE Health, Inc. For: Aug 06

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885438.html

Form 8-K SANUWAVE Health, Inc. For: Aug 06

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885438.html

Sanuwave Announces Q2 FY2026 Financial Results

Thu, 06 Aug 2026 17:00:00 -0400

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025.

Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.

GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025.

EDEN PRAIRIE, Minn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-cleared wound care products, is pleased to provide its financial results for the three months ended June 30, 2026.

Sanuwave Announces Q2 FY2026 Financial Results

Thu, 06 Aug 2026 17:00:00 -0400

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025.

Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.

GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025.

Form 10-Q SANUWAVE Health, Inc. For: Jun 30

Thu, 06 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260806/26884933.html

Form 10-Q SANUWAVE Health, Inc. For: Jun 30

Thu, 06 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260806/26884933.html

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: Opaleye Management Inc.

Fri, 31 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26850642.html

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: Opaleye Management Inc.

Fri, 31 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26850642.html

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

Thu, 30 Jul 2026 18:00:00 -0400

EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 7, 2026, at 8:30 AM (ET) to present its Q2 2026 financial results.

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information
Toll Free: 1-800-274-8461
Toll/International: 1-203-518-9814
Conference ID: SANUWAVE

OR click the link below to access the live webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1771327&tp_key=110b588de5
Materials for the conference call will be

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

Thu, 30 Jul 2026 18:00:00 -0400

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information
Toll Free: 1-800-274-8461
Toll/International: 1-203-518-9814
Conference ID: SANUWAVE

OR click the link below to access the live webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1771327&tp_key=110b588de5
Materials for the conference call will be

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260730/26841306.html

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260730/26841306.html

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260730/26841306.html

Form 8-K SANUWAVE Health, Inc. For: Jul 13

Mon, 13 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26762936.html

Form 8-K SANUWAVE Health, Inc. For: Jul 13

Mon, 13 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26762936.html

Form 8-K SANUWAVE Health, Inc. For: Jul 13

Mon, 13 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26762936.html

Sanuwave Q2 2026 revenue tops revised guidance range

Mon, 13 Jul 2026 16:31:09 -0400

Sanuwave Health, Inc. (NASDAQ: SNWV) reported preliminary, unaudited second-quarter 2026 revenue of $9.6 million to $9.8 million, above the high end of its revised guidance range of $8.5 million to $9.5 million, according to a press release.

The preliminary figures represent a decrease of approximately 3% to 5% compared with revenue of $10.1 million in the second quarter of 2025.

CEO Morgan Frank attributed capital sales weakness to stress in the company's customer base and the presence of used Ultramist systems in the secondary market. "The business played out largely as we had forecast with capital sales facing headwinds from stress in

Sanuwave Q2 2026 revenue tops revised guidance range

Mon, 13 Jul 2026 16:31:09 -0400

The preliminary figures represent a decrease of approximately 3% to 5% compared with revenue of $10.1 million in the second quarter of 2025.

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

Mon, 13 Jul 2026 16:30:00 -0400

Sanuwave announces preliminary, unaudited revenues of $9.6 million to $9.8 million for the second quarter ended June 30, 2026, above the high end of the Company’s revised guidance of $8.5 to $9.5 million

EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6 to $9.8 million, above the high end of the revised guidance range of $8.5 to $9.5 million

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

Mon, 13 Jul 2026 16:30:00 -0400

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Blizard Jeffrey

Thu, 02 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260702/26727897.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Blizard Jeffrey

Thu, 02 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260702/26727897.html